May 08, 2025

FDA Warns Physicians of Tianeptine Dangers

The FDA warns physicians about unapproved tianeptine products that are linked to severe adverse events, including dependence, toxicity, and death.

Conexiant

May 08, 2025

mRNA Combo Vaccine Effective Against Respiratory Viruses

A phase III trial of mRNA-1083 demonstrates immunogenicity and acceptable safety profile in adults 50 years and older.

Conexiant

May 07, 2025

Dr. Vinay Prasad Shakes Up FDA Leadership

The FDA has appointed Vinay Prasad as its new vaccine chief, shaking up biotech stocks and signaling potential shifts in drug approvals.

Reuters

May 06, 2025

FDA Approves TAVR Platform for Asymptomatic AS

The FDA has approved the SAPIEN 3 TAVR platform for patients with asymptomatic severe aortic stenosis based on data from the EARLY TAVR trial.

Conexiant

May 05, 2025

FDA Monthly Round-up: Key April Updates

April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.

Conexiant

April 30, 2025

New Phase III Data on Brensocatib Therapy

Phase III trial results show that once-daily brensocatib reduces pulmonary exacerbations and slows lung function decline in patients with bronchiectasis.

Conexiant

April 30, 2025

New Phase III Data: Sotatercept for PAH

Sotatercept reduced the composite risk of death, lung transplantation, or hospitalization for worsening pulmonary arterial hypertension by nearly 75% compared with placebo in high-risk patients in a phase III trial.

Conexiant

April 29, 2025

Foley Catheter Management: New Best Practices, Pitfalls

Foley catheter use is associated with a wide range of complications, from infections to urethral erosion.

Conexiant

April 29, 2025

Flu Shots Linked to Temporary Menstrual Changes

Study shows small, temporary cycle length increases after vaccination

Conexiant